Afficher la notice abrégée

Antihypertensive and lipid-lowering drugs usage after primary stroke in a large representative sample of the French population

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPERRIER, Julia
dc.contributor.authorOLIE, Valerie
dc.contributor.authorGABET, Amelie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTZOURIO, Christophe
IDREF: 69829209
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
dc.date.accessioned2022-03-07T11:30:24Z
dc.date.available2022-03-07T11:30:24Z
dc.date.issued2022-01-06
dc.identifier.issn1472-8206 (Electronic) 0767-3981 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/128852
dc.description.abstractEnOBJECTIVES: To describe the use of antihypertensive and lipid-lowering drugs in post-stroke secondary prevention in France. METHODS AND RESULTS: A prospective cohort study based on a representative sample of the French health insurance system database. All patients aged 45 and over, hospitalized for a first stroke between 1 January 2009 and 31 December 2014 were included. For each drug class, identified using ATC codes, patients were followed from the first drug supply after stroke until the end of study period (31 December 2017), or exit date of the database or death. Adherence was defined by the proportion of days covered and persistence by the absence of a treatment gap of more than 91-days. A total of 2,674 patients were include, median age was 75.0 years (interquartile range 63.0-83.0) and 51.2% were women. For patients treated with a drug of interest after stroke, median follow-up was 4.8 years (interquartile range 3.4-6.5). Regarding antihypertensive drugs, adherence at 8 yrs was 84.1% and persistence was 71.0%. For lipid-lowering drugs adherence at 8 yrs was 68.6% and persistence was 49.4%. Adherence and persistence were lower for patients starting treatment at time of stroke (antihypertensive drugs: 70.9% for adherence and 52.6% for persistence; lipid-lowering drugs: 62.3% and 43.1%) compared to patients already treated (antihypertensive drugs: 87.2% and 75.2%; lipid-lowering drugs: 73.6% and 54.5%). CONCLUSION: In this large representative sample of patients hospitalized for a first stroke in France, post-stroke therapeutic management remains suboptimal compared to guidelines, notably regarding lipid-lowering drugs. This trend was more pronounced for newly treated patients.
dc.language.isoENen_US
dc.subject.enAntihypertensive drugs
dc.subject.enLipid-lowering drugs
dc.subject.enSecondary prevention
dc.subject.enStroke
dc.subject.enUsage
dc.title.enAntihypertensive and lipid-lowering drugs usage after primary stroke in a large representative sample of the French population
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/fcp.12756en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34990035en_US
bordeaux.journalFundamental and Clinical Pharmacologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.teamHEALTHY_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03599633
hal.version1
hal.date.transferred2022-03-07T11:30:26Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Fundamental%20and%20Clinical%20Pharmacology&rft.date=2022-01-06&rft.eissn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.issn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.au=PERRIER,%20Julia&OLIE,%20Valerie&GABET,%20Amelie&TZOURIO,%20Christophe&BEZIN,%20Julien&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée